Latest

Super Micro Computer: The Time Correction Is Not Yet Over (Archive)

SMCI’s stellar AI-driven growth persists, but margins, ROICs, and valuation temper conviction.

Pfizer: Too Early For A Turnaround (Archive)

Pfizer’s oncology pivot and CEO incentives cloud the timing and quality of any turnaround.

Palantir: Insider Sales And High Valuations Vs. Strong Operational Performance (Archive)

Palantir’s strong execution contrasts with heavy insider selling and stretched valuations.

Microsoft: Superior Focus On Azure And ARPU Growth To Drive Outperformance (Archive)

Azure’s accelerating momentum, ARPU gains, and technicals position Microsoft for sustained outperformance.

Berkshire Hathaway: Why I Still Think It Will Likely Underperform The Market (Archive)

Apple concentration, manufacturing weakness and fair-value valuation point to negative alpha ahead.

British American Tobacco: It's Still A Value Trap, But I'm Lifting My 'Sell' View (Archive)

British American Tobacco remains a cheap but catalyst-starved value trap, warranting only a cautious hold.

Oxford Lane Capital: Fundamental Issues Aside, Rate Cuts Are A Tailwind (Archive)

Rate cuts offer OXLC a fragile tailwind amid chronic cash flow and NAV erosion.